[go: up one dir, main page]

AR058598A1 - Administracion transdermica de meptazinol - Google Patents

Administracion transdermica de meptazinol

Info

Publication number
AR058598A1
AR058598A1 ARP060105700A ARP060105700A AR058598A1 AR 058598 A1 AR058598 A1 AR 058598A1 AR P060105700 A ARP060105700 A AR P060105700A AR P060105700 A ARP060105700 A AR P060105700A AR 058598 A1 AR058598 A1 AR 058598A1
Authority
AR
Argentina
Prior art keywords
meptazinol
transdermal administration
administration
increases
disclosed
Prior art date
Application number
ARP060105700A
Other languages
English (en)
Inventor
Richard Franklin
Original Assignee
Shire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Pharmaceuticals Inc filed Critical Shire Pharmaceuticals Inc
Publication of AR058598A1 publication Critical patent/AR058598A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se divulga un sistema de administracion para la administracion de una sal de meptazinol o precursor de meptazinol que aumenta la biodisponibilidad del meptazinol a través de una cantidad eficaz para brindar un alivio analgésico. Una realizacion del sistema de administracion es un dispositivo transdérmico que aumenta el flujo del meptazinol en la piel a través de una cantidad eficaz para brindar un alivio analgésico. También se divulgan los métodos para brindar un alivio analgésico.
ARP060105700A 2005-12-21 2006-12-21 Administracion transdermica de meptazinol AR058598A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75335705P 2005-12-21 2005-12-21
US86211406P 2006-10-19 2006-10-19

Publications (1)

Publication Number Publication Date
AR058598A1 true AR058598A1 (es) 2008-02-13

Family

ID=38198475

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105700A AR058598A1 (es) 2005-12-21 2006-12-21 Administracion transdermica de meptazinol

Country Status (15)

Country Link
US (1) US20070224253A1 (es)
EP (1) EP1962817B1 (es)
AR (1) AR058598A1 (es)
AT (1) ATE488229T1 (es)
AU (1) AU2006331596A1 (es)
CA (1) CA2633369A1 (es)
DE (1) DE602006018355D1 (es)
DK (1) DK1962817T3 (es)
EA (1) EA200801575A1 (es)
MX (1) MX2008008050A (es)
PE (1) PE20071163A1 (es)
PT (1) PT1962817E (es)
TW (1) TW200800223A (es)
UY (1) UY30056A1 (es)
WO (1) WO2007075883A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280064A1 (en) * 2005-06-24 2009-11-12 Rao Papineni Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans
EP2041214A4 (en) 2006-07-10 2009-07-08 Medipacs Inc SUPERELASTIC EPOXY HYDROGEL
EP2227635A2 (en) 2007-12-03 2010-09-15 Medipacs, Inc. Fluid metering device
WO2009092071A2 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid and peptide pro-drugs of phenolic analgesics and uses thereof
US8996104B2 (en) * 2008-06-25 2015-03-31 Fe3 Medical, Inc. Patches and method for the transdermal delivery of a therapeutically effective amount of iron
US8961492B2 (en) 2009-02-12 2015-02-24 Incube Labs, Llc System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation
US8190252B2 (en) 2009-02-12 2012-05-29 Incube Labs, Llc Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes
WO2010093472A2 (en) * 2009-02-12 2010-08-19 Incube Labs, Llc Method and apparatus for oscillatory iontophoretic transdermal delivery of a therapeutic agent
US8821945B2 (en) * 2009-04-25 2014-09-02 Fe3 Medical, Inc. Method for transdermal iontophoretic delivery of chelated agents
US8417330B2 (en) * 2009-06-26 2013-04-09 Incube Labs, Llc Corrosion resistant electrodes for iontophoretic transdermal delivery devices and methods of use
US9238102B2 (en) 2009-09-10 2016-01-19 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
WO2011044175A2 (en) 2009-10-06 2011-04-14 Incube Labs, Llc Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes
US8685038B2 (en) 2009-12-07 2014-04-01 Incube Labs, Llc Iontophoretic apparatus and method for marking of the skin
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
EP2531047B1 (en) 2010-02-05 2024-11-13 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
WO2011100376A2 (en) 2010-02-10 2011-08-18 Incube Labs, Llc Methods and architecture for power optimization of iontophoretic transdermal drug delivery
WO2011120084A1 (en) 2010-03-30 2011-10-06 Phosphagenics Limited Transdermal delivery patch
US8668675B2 (en) 2010-11-03 2014-03-11 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
EP2685992A4 (en) 2011-03-15 2014-09-10 Phosphagenics Ltd AMINOCHINOLINE AS A KINASEHEMMER
CN103826696B (zh) 2011-03-24 2017-03-22 因卡伯实验室有限责任公司 用于治疗剂的两阶段经皮离子电渗递送的系统及方法
WO2012154704A2 (en) 2011-05-06 2012-11-15 Incube Labs, Llc System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings
US8636696B2 (en) 2011-06-10 2014-01-28 Kimberly-Clark Worldwide, Inc. Transdermal device containing microneedles
JP2015510956A (ja) 2012-03-14 2015-04-13 メディパックス インコーポレイテッド 過剰反応性分子を含むスマートポリマー材料
BR112015020328B1 (pt) 2013-02-28 2022-05-31 Sorrento Therapeutics, Inc Dispositivo de aplicação transdérmica de droga
EP2961469A4 (en) 2013-02-28 2016-10-26 Kimberly Clark Co DEVICE FOR DELIVERY OF MEDICAMENT
US10376308B2 (en) 2015-02-05 2019-08-13 Axon Therapies, Inc. Devices and methods for treatment of heart failure by splanchnic nerve ablation
JP6882321B2 (ja) 2015-12-09 2021-06-02 フォスファージニクス リミテッド 医薬製剤
EP3490442A4 (en) 2016-07-29 2020-03-25 Axon Therapies, Inc. Devices, systems, and methods for treatment of heart failure by splanchnic nerve ablation
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
WO2019118976A1 (en) 2017-12-17 2019-06-20 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
JP7334167B2 (ja) 2018-01-26 2023-08-28 アクソン セラピーズ，インク． 内臓神経の血管内アブレーションの為の方法及びデバイス
WO2020257763A1 (en) 2019-06-20 2020-12-24 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
WO2021146724A1 (en) 2020-01-17 2021-07-22 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
CN113491675B (zh) * 2021-07-01 2023-05-23 北京航空航天大学 一种预防瘢痕的微针创口贴及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1539277A (en) * 1977-09-16 1979-01-31 Wyeth John & Brother Ltd Hexahydro-1h-azepines
IE55189B1 (en) * 1982-07-08 1990-06-20 Wyeth John & Brother Ltd Pharmaceutical compositions
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US6916486B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
DE69939019D1 (de) * 1998-07-07 2008-08-14 Transdermal Technologies Inc Zusammensetzungen für die schnelle und nicht-irritierende transdermale verabreichung von pharmazeutika and verfahren zur formuliering davon und ihren verabreichung
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
DE10059415A1 (de) * 2000-11-30 2002-06-06 Gruenenthal Gmbh Verwendung von schwachen Opioiden und gemischten Opioidagonisten/-antagonisten zur Therapie der Harninkontinenz
DE60326354D1 (de) * 2002-08-20 2009-04-09 Euro Celtique Sa Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form
ME00276B (me) * 2003-04-30 2011-05-10 Purdue Pharma Lp Transdermalni dozni oblik otporan na promjene koje sadrže komponentu aktivnog sredstva i komponentu suprotnog sredstva na mjestu koji je ispod sloja aktivnog sredstva

Also Published As

Publication number Publication date
MX2008008050A (es) 2009-04-06
UY30056A1 (es) 2007-06-29
US20070224253A1 (en) 2007-09-27
PT1962817E (pt) 2010-12-13
DE602006018355D1 (de) 2010-12-30
WO2007075883A2 (en) 2007-07-05
WO2007075883A9 (en) 2007-08-23
PE20071163A1 (es) 2007-11-30
DK1962817T3 (da) 2011-03-07
EP1962817A2 (en) 2008-09-03
EP1962817B1 (en) 2010-11-17
TW200800223A (en) 2008-01-01
ATE488229T1 (de) 2010-12-15
CA2633369A1 (en) 2007-07-05
WO2007075883A3 (en) 2008-01-17
EA200801575A1 (ru) 2008-12-30
AU2006331596A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
AR058598A1 (es) Administracion transdermica de meptazinol
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CR20140321A (es) Sistema de administracion transdermica que contiene buprenofina
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
DOP2012000238A (es) Compuestos de para la inhibición de inmunoproteasomas
PE20191796A1 (es) Composicion farmaceutica de clorhidrato de s-ketamina
CL2015001891A1 (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas; uso para tratar el dolor; y metodo de preparacion. (divisional de la solicitud n°2754-2014).
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
UY32455A (es) Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia
GT201200247A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
CL2015002847A1 (es) Sistemas y métodos para tratar una respuesta farmacodinámica adversa inducida por opioides (divisional de la solicitud n° 0110-2015).
BR112013012117A8 (pt) Sistema de distribuição de fármaco iontoforético coempacotado de utilização única coempacotado autocontido, usos de fármaco e de composto de triptano
CR20150360A (es) Sistema de liberación transdérmica
CL2008001605A1 (es) Una formulacion de dosis intranasal que comprende asenapina o una sal farmaceuticamente aceptable y un portador liquido que contiene agua y un poliol, util para el tratamiento de la esquizofrenia.
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
CL2012002437A1 (es) Uso de antiinflamatorio no esteroide (aine) o una sal farmacologicamente aceptable del mismo para preparar un medicamento util para el tratamiento de enfermedades renales cronicas en gatos.
MX2017012926A (es) Inhibidores y sus usos.
CL2008003006A1 (es) Uso de ester metilico del acido (-)-(3ar,4s,7ar)-4-hidroxi-4-m-toliletinil-octahidro-indol-1-carboxilico en base libre o en forma de sal para el tratamiento, prevencion o retraso de la progresion de la disquinesia de parkinson asociada a l-dopa; uso de la composicion farmaceutica; uso de una composicion que ademas comprende l-dopa.
UA108200C2 (uk) Лікарські форми та способи застосування ектопаразитоцидів
BR112012014107B8 (pt) sistema terapêutico transdérmico (tts) e processo de produção de tts
BR112015032256A2 (pt) dispositivo com sistema terapêutico transdérmico e auxiliar de posicionamento e penetração
ATE524167T1 (de) Transdermales pflaster
CL2008002465A1 (es) Composición farmacéutica anhidra tópica, que comprende derivados de niacina y un portador aceptable, su aplicacón permite un bienestar sexual mejorado.
DOP2007000055A (es) Composición farmaceutica que comprende un analgésico y vitaminas
EA201301021A1 (ru) Применение пригодной для распыления композиции, содержащей амброксол

Legal Events

Date Code Title Description
FB Suspension of granting procedure